David R. Gandara - Concepedia

Author

David R. Gandara

University of California, Davis

Also Known As

D Gandara, D R Gandara, D. GANDARA, D. Gandara, D. R. Gandara, David Gandara, David R Gandara, David R. Gandara

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

University of California, Davis City Of Hope National Medical Center University of Southern California City of Hope University of Chicago

About

David R. Gandara is an author at University of California, Davis specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	21	1.4K
2	Immunology	3	3	104
3	Hepatology	2	2	302
4	Health Sciences	1	1	101
5	Nephrology	1	1	32

David R. Gandara

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer Ramesh K. Ramanathan, Chandra P. Belani, D. A. Singh, Cancer Chemotherapy and Pharmacology HepatologyMedicineBiliary CancerPathologyPhase Ii Study	2009	286
Trastuzumab plus docetaxel in HER‐2/<i>neu</i>‐positive prostate carcinoma Primo N. Lara, Karen Giselle Chee, Jeff Longmate, Cancer	2004	114
Trastuzumab plus Docetaxel in HER2/neu–Positive Non–Small-Cell Lung Cancer: A California Cancer Consortium Screening and Phase II Trial Primo N. Lara, Luko Laptalo, Jeff Longmate, Clinical Lung Cancer Phase Ii TrialMedicinePathologyBronchial NeoplasmCancer Treatment	2004	108
GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. Paul J. Hesketh, William K. Murphy, Eric P. Lester, Journal of Clinical Oncology Drug SafetyMedicinePharmacologyClinical TrialsNovel Compound	1989	101
The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial Primo N. Lara, Philip C. Mack, Timothy W. Synold, Clinical Cancer Research	2005	96
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study Primo N. Lara, Jeff Longmate, Christopher P. Evans, Anti-Cancer Drugs UrologyPhase Ii TrialGenitourinary CancerMedicinePharmacology	2009	94
The AKT Inhibitor Perifosine in Biochemically Recurrent Prostate Cancer: A Phase II California/Pittsburgh Cancer Consortium Trial Karen Giselle Chee, Jeff Longmate, David I. Quinn, Clinical Genitourinary Cancer UrologyAkt Inhibitor PerifosineOncologyGenitourinary CancerMedicine	2007	93
Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial Przemyslaw Twardowski, Walter M. Stadler, Paul Frankel, Urology Metastatic Urothelial CancerUrologyGenitourinary CancerMedicinePhase Ii Study	2010	86
Dolastatin-10 in Metastatic Melanoma: A Phase II and Pharmokinetic Trial of the California Cancer Consortium Kim Margolin, Jeff Longmate, Timothy W. Synold, Investigational New Drugs California Cancer ConsortiumPhase IiMedicineMelanomaPharmacology	2001	82
Phase II Study of Cediranib (AZD 2171), an Inhibitor of the Vascular Endothelial Growth Factor Receptor, for Second-Line Therapy of Small Cell Lung Cancer (National Cancer Institute #7097) Suresh S. Ramalingam, Chandra P. Belani, Philip C. Mack, Journal of Thoracic Oncology National Cancer InstituteAzd 2171MedicinePharmacologyPhase Ii Study	2010	79

Page 1